Covered recipient · General Payments record
FAYZ A HUDEFI
Allopathic & Osteopathic Physicians Psychiatry & Neurology Addiction Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$346.37
4 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $346.37 | 4 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alkermes, Inc. | $326.26 | 3 |
| Sunovion Pharmaceuticals Inc. | $20.11 | 1 |
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
FAYZ A HUDEFI
NPI 1992740393 · CMS profile ID 135740
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Addiction Medicine
FORT SMITH, AR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1992740393?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- FAYZ A HUDEFI, NPI 1992740393, CMS profile ID 135740. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992740393?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). FAYZ A HUDEFI, NPI 1992740393, CMS profile ID 135740. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992740393?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- FAYZ A HUDEFI, NPI 1992740393, CMS profile ID 135740, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1992740393?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
4 matching records · $346.37 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–4 of 4.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Alkermes, Inc. | $85.38 | 12/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 686596253 | CMS |
| Sunovion Pharmaceuticals Inc. | $20.11 | 12/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687932115 | CMS |
| Alkermes, Inc. | $122.90 | 11/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 686596255 | CMS |
| Alkermes, Inc. | $117.98 | 05/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 686596257 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,184,915.74 | 413 |
| PY2024 | Principal investigator | $2,303,282.98 | 204 |
| PY2023 | Principal investigator | $6,541,371.44 | 120 |
| PY2022 | Principal investigator | $34,086.76 | 8 |
| PY2021 | Principal investigator | $312,565.61 | 85 |
| PY2020 | Recipient | $1,312.46 | 7 |
| PY2020 | Principal investigator | $543,799.24 | 155 |
| PY2019 | Recipient | $2,502.81 | 13 |
| PY2019 | Principal investigator | $1,252,649.46 | 132 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
145 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Allergan Inc. | $165.00 | 12/31/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA | No dispute reported | 06/30/2026 | 670118209 |
| Principal investigator 1 | Allergan Inc. | $165.00 | 12/31/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670118989 |
| Principal investigator 1 | Allergan Inc. | $266.96 | 12/31/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670119373 |
| Principal investigator 1 | Allergan Inc. | $2,450.24 | 12/31/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC | No dispute reported | 06/30/2026 | 670119788 |
| Principal investigator 1 | Allergan Inc. | $500.00 | 12/31/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670119978 |
| Principal investigator 1 | Corcept Therapeutics | $5,000.00 | 12/04/2019 | Non-covered Recipient Entity Pillar Clinical Research, LLC | CORT118335-876 | No dispute reported | 06/30/2026 | 695141209 |
| Principal investigator 1 | Corcept Therapeutics | $1,000.00 | 12/04/2019 | Non-covered Recipient Entity Pillar Clinical Research, LLC | CORT118335-876 | No dispute reported | 06/30/2026 | 695141215 |
| Principal investigator 1 | Corcept Therapeutics | $800.00 | 12/04/2019 | Non-covered Recipient Entity Pillar Clinical Research, LLC | CORT118335-876 | No dispute reported | 06/30/2026 | 695141225 |
| Principal investigator 1 | Corcept Therapeutics | $5,200.00 | 12/04/2019 | Non-covered Recipient Entity Pillar Clinical Research, LLC | CORT118335-876 | No dispute reported | 06/30/2026 | 695141231 |
| Principal investigator 1 | Corcept Therapeutics | $1,500.00 | 12/04/2019 | Non-covered Recipient Entity Pillar Clinical Research, LLC | CORT118335-876 | No dispute reported | 06/30/2026 | 695141236 |
| Principal investigator 1 | Corcept Therapeutics | $3,000.00 | 12/04/2019 | Non-covered Recipient Entity Pillar Clinical Research, LLC | CORT118335-876 | No dispute reported | 06/30/2026 | 695141241 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $6,669.85 | 11/27/2019 | Non-covered Recipient Entity PROSCIENCERESEARCHGROUP LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | No dispute reported | 06/30/2026 | 696055155 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 10/31/2019 | Non-covered Recipient Entity WOODLAND INTERNATIONAL RESEARCH GROUP | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | No dispute reported | 06/30/2026 | 653526157 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 10/31/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | No dispute reported | 06/30/2026 | 653526167 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $48.16 | 10/28/2019 | Non-covered Recipient Entity WOODLAND RSRCH NORTHWEST, LLC | BI 425809 Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 703924877 |
| Recipient | Corcept Therapeutics | $287.00 | 10/22/2019 | Covered Recipient Physician | Study 876 | No dispute reported | 06/30/2026 | 695141289 |
| Recipient | Corcept Therapeutics | $155.46 | 10/22/2019 | Covered Recipient Physician | Study 876 | No dispute reported | 06/30/2026 | 695141294 |
| Recipient | Corcept Therapeutics | $152.42 | 10/22/2019 | Covered Recipient Physician | Study 876 | No dispute reported | 06/30/2026 | 695141298 |
| Principal investigator 1 | LEO Pharma AS | $5,469.00 | 10/22/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST LLC | TRALOKINUMAB DRUG INTERACTION TRAIL | No dispute reported | 06/30/2026 | 686859665 |
| Principal investigator 1 | Alkermes, Inc. | $68.91 | 10/16/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | No dispute reported | 06/30/2026 | 653526165 |
| Principal investigator 1 | TOLMAR, INC. | $2,953.00 | 10/15/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | TOL3010B | No dispute reported | 06/30/2026 | 638019611 |
| Recipient | Corcept Therapeutics | $87.68 | 10/14/2019 | Covered Recipient Physician | Study 876 | No dispute reported | 06/30/2026 | 695141281 |
| Recipient | Corcept Therapeutics | $49.26 | 10/14/2019 | Covered Recipient Physician | Study 876 | No dispute reported | 06/30/2026 | 695141285 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $3,147.75 | 10/10/2019 | Non-covered Recipient Entity PSYCHIATRIC CARE & RESEARCH CENTER | AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 696055017 |
| Recipient | Otsuka Pharmaceutical Development & Commercialization, Inc. | $128.75 | 10/04/2019 | Covered Recipient Physician | A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | No dispute reported | 06/30/2026 | 696050037 |
| Recipient | Otsuka Pharmaceutical Development & Commercialization, Inc. | $50.00 | 10/04/2019 | Covered Recipient Physician | A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | No dispute reported | 06/30/2026 | 696050039 |
| Recipient | Otsuka Pharmaceutical Development & Commercialization, Inc. | $50.00 | 10/04/2019 | Covered Recipient Physician | A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | No dispute reported | 06/30/2026 | 696050043 |
| Recipient | Otsuka Pharmaceutical Development & Commercialization, Inc. | $201.71 | 10/04/2019 | Covered Recipient Physician | A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | No dispute reported | 06/30/2026 | 696050047 |
| Recipient | Otsuka Pharmaceutical Development & Commercialization, Inc. | $678.90 | 10/03/2019 | Covered Recipient Physician | A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | No dispute reported | 06/30/2026 | 696050025 |
| Recipient | Otsuka Pharmaceutical Development & Commercialization, Inc. | $128.75 | 10/03/2019 | Covered Recipient Physician | A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | No dispute reported | 06/30/2026 | 696050029 |
| Recipient | Otsuka Pharmaceutical Development & Commercialization, Inc. | $124.99 | 10/03/2019 | Covered Recipient Physician | A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | No dispute reported | 06/30/2026 | 696050033 |
| Principal investigator 1 | Biogen, Inc. | $13,454.00 | 10/01/2019 | Non-covered Recipient Entity Pillar Clinical Research | A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) | No dispute reported | 06/30/2026 | 675311123 |
| Principal investigator 2 | LEO Pharma AS | $924.00 | 10/01/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST LLC | TRALOKINUMAB DRUG INTERACTION TRAIL | No dispute reported | 06/30/2026 | 686859038 |
| Principal investigator 1 | TOLMAR, INC. | $4,465.80 | 09/04/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | TOL3010B | No dispute reported | 06/30/2026 | 638019607 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 09/01/2019 | Non-covered Recipient Entity WOODLAND RSRCH NORTHWEST, LLC | BI 425809 Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 703921919 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 08/31/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | No dispute reported | 06/30/2026 | 653526211 |
| Recipient | Corcept Therapeutics | $407.89 | 08/30/2019 | Covered Recipient Physician | Study 876 | No dispute reported | 06/30/2026 | 695141275 |
| Principal investigator 1 | Eisai Inc. | $300.30 | 08/22/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY DBA ST LOUIS CLINICAL TRIALS | A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder | No dispute reported | 06/30/2026 | 702547909 |
| Principal investigator 1 | Alkermes, Inc. | $124.24 | 08/16/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | No dispute reported | 06/30/2026 | 653526229 |
| Principal investigator 2 | LEO Pharma AS | $1,350.00 | 08/13/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST LLC | TRALOKINUMAB DRUG INTERACTION TRAIL | No dispute reported | 06/30/2026 | 686857651 |
| Principal investigator 1 | Allergan Inc. | $5,643.30 | 08/06/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. | No dispute reported | 06/30/2026 | 670063585 |
| Principal investigator 2 | LEO Pharma AS | $1,990.00 | 08/06/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST LLC | TRALOKINUMAB DRUG INTERACTION TRAIL | No dispute reported | 06/30/2026 | 686857239 |
| Principal investigator 1 | Allergan Inc. | $19,999.40 | 08/01/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC | No dispute reported | 06/30/2026 | 670062159 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 07/31/2019 | Non-covered Recipient Entity WOODLAND INTERNATIONAL RESEARCH GROUP | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | No dispute reported | 06/30/2026 | 653526155 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 07/31/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526189 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 07/31/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526191 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 07/31/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | No dispute reported | 06/30/2026 | 653526207 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 07/31/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | No dispute reported | 06/30/2026 | 653526209 |
| Principal investigator 1 | Allergan Inc. | $29,400.00 | 07/30/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC | No dispute reported | 06/30/2026 | 670061661 |
| Principal investigator 1 | Allergan Inc. | $73,146.20 | 07/09/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC | No dispute reported | 06/30/2026 | 670055227 |
| Principal investigator 1 | Alkermes, Inc. | $147.15 | 07/08/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | No dispute reported | 06/30/2026 | 653526205 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $17,220.64 | 07/03/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | No dispute reported | 06/30/2026 | 696054649 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 06/30/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526187 |
| Principal investigator 1 | Alkermes, Inc. | $651.90 | 06/04/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526185 |
| Principal investigator 1 | Genentech, Inc. | $175.00 | 06/04/2019 | Non-covered Recipient Entity ERG HOLDING CO LLC | PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD | No dispute reported | 06/30/2026 | 681082101 |
| Principal investigator 1 | Alkermes, Inc. | $4,072.80 | 06/03/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | No dispute reported | 06/30/2026 | 653526227 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $8,486.85 | 05/27/2019 | Non-covered Recipient Entity PROSCIENCERESEARCHGROUP LLC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. | No dispute reported | 06/30/2026 | 696054487 |
| Principal investigator 1 | Alkermes, Inc. | $35.00 | 05/25/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526183 |
| Principal investigator 1 | Alkermes, Inc. | $150.00 | 05/24/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | No dispute reported | 06/30/2026 | 653526225 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $8,000.00 | 05/20/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 696054423 |
| Principal investigator 1 | Alkermes, Inc. | $100.00 | 05/17/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | No dispute reported | 06/30/2026 | 653526223 |
| Principal investigator 1 | Allergan Inc. | $14,574.90 | 05/16/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA | No dispute reported | 06/30/2026 | 670046147 |
| Principal investigator 1 | Genentech, Inc. | $1,700.00 | 05/15/2019 | Non-covered Recipient Entity ERG HOLDING CO LLC | PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD | No dispute reported | 06/30/2026 | 681083021 |
| Principal investigator 1 | Allergan Inc. | $18,146.90 | 05/14/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC | No dispute reported | 06/30/2026 | 670044627 |
| Principal investigator 1 | Alkermes, Inc. | $1,546.80 | 05/07/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | No dispute reported | 06/30/2026 | 653526221 |
| Principal investigator 1 | Alkermes, Inc. | $1,853.70 | 05/06/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526181 |
| Principal investigator 1 | Alkermes, Inc. | $35.00 | 05/03/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526179 |
| Principal investigator 1 | Genentech, Inc. | $215.00 | 04/29/2019 | Non-covered Recipient Entity ERG HOLDING CO LLC | PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD | No dispute reported | 06/30/2026 | 681081593 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $221.00 | 04/25/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686565835 |
| Principal investigator 1 | Alkermes, Inc. | $48.13 | 04/19/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | No dispute reported | 06/30/2026 | 653526243 |
| Principal investigator 1 | Genentech, Inc. | $1,804.00 | 04/18/2019 | Non-covered Recipient Entity ERG HOLDING CO LLC | PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD | No dispute reported | 06/30/2026 | 681079841 |
| Principal investigator 1 | Alkermes, Inc. | $45.94 | 04/16/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | No dispute reported | 06/30/2026 | 653526163 |
| Principal investigator 1 | Alkermes, Inc. | $46.59 | 04/16/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | No dispute reported | 06/30/2026 | 653526219 |
| Principal investigator 1 | Alkermes, Inc. | $27.76 | 04/15/2019 | Non-covered Recipient Entity Woodland Research | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526159 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 04/15/2019 | Non-covered Recipient Entity Woodland Research | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526161 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $5,731.47 | 04/12/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC | A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 using Risperidone as Active Control in Subjects Experiencing an AcuteEpisode of Schizophrenia. | No dispute reported | 06/30/2026 | 691316165 |
| Principal investigator 1 | Allergan Inc. | $16,492.50 | 04/11/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670037235 |
| Principal investigator 1 | LEO Pharma AS | $10,131.00 | 04/11/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST LLC | TRALOKINUMAB DRUG INTERACTION TRAIL | No dispute reported | 06/30/2026 | 686854039 |
| Principal investigator 1 | LEO Pharma AS | $162.00 | 04/11/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST LLC | TRALOKINUMAB DRUG INTERACTION TRAIL | No dispute reported | 06/30/2026 | 686854045 |
| Principal investigator 1 | Alkermes, Inc. | $1,000.00 | 04/10/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | No dispute reported | 06/30/2026 | 653526241 |
| Principal investigator 1 | Allergan Inc. | $4,204.70 | 04/09/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA | No dispute reported | 06/30/2026 | 670036645 |
| Principal investigator 1 | Allergan Inc. | $25,718.40 | 04/09/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC | No dispute reported | 06/30/2026 | 670036691 |
| Principal investigator 1 | Alkermes, Inc. | $70.00 | 04/06/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526177 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $3,397.00 | 04/05/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED TRIAL OF BREXPIPRAZOLE 1 - 3 MGDAY AS MONOTHERAPY OR AS COMBINATION THERAPY IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER | No dispute reported | 06/30/2026 | 696053947 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $5.65 | 04/04/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686565473 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $5.65 | 04/04/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686565549 |
| Principal investigator 1 | Alkermes, Inc. | $228.00 | 03/31/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | No dispute reported | 06/30/2026 | 653526239 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $743.00 | 03/21/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686565259 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $37.90 | 03/20/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 685006503 |
| Principal investigator 1 | Eisai Inc. | $6,593.40 | 03/19/2019 | Non-covered Recipient Entity CLINICAL PHARMACOLOGY OF MIAMI, INC. | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia | No dispute reported | 06/30/2026 | 702547907 |
| Principal investigator 1 | Genentech, Inc. | $6,012.00 | 03/18/2019 | Non-covered Recipient Entity ERG HOLDING CO LLC | PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD | No dispute reported | 06/30/2026 | 681086297 |
| Principal investigator 1 | Allergan Inc. | $3,106.50 | 03/14/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670030621 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $59.80 | 03/13/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 685006501 |
| Principal investigator 1 | Allergan Inc. | $1,264.45 | 03/12/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC | No dispute reported | 06/30/2026 | 670029931 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $29,385.19 | 03/06/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. | No dispute reported | 06/30/2026 | 696053485 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $29,700.00 | 03/06/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 685006493 |
| Principal investigator 1 | Allergan Inc. | $5,000.00 | 03/05/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670029005 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 02/28/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526175 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 02/28/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | No dispute reported | 06/30/2026 | 653526203 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 02/22/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526193 |
| Principal investigator 1 | Allergan Inc. | $16,340.00 | 02/21/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670026115 |
| Principal investigator 1 | Allergan Inc. | $4,750.00 | 02/19/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA | No dispute reported | 06/30/2026 | 670025787 |
| Principal investigator 1 | Allergan Inc. | $5,750.00 | 02/19/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA | No dispute reported | 06/30/2026 | 670025911 |
| Principal investigator 1 | Alkermes, Inc. | $45.94 | 02/15/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | No dispute reported | 06/30/2026 | 653526199 |
| Principal investigator 1 | Alkermes, Inc. | $54.55 | 02/15/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | No dispute reported | 06/30/2026 | 653526201 |
| Principal investigator 1 | Alkermes, Inc. | $155.30 | 02/15/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | No dispute reported | 06/30/2026 | 653526215 |
| Principal investigator 1 | Alkermes, Inc. | $750.27 | 02/15/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | No dispute reported | 06/30/2026 | 653526217 |
| Principal investigator 1 | LEO Pharma AS | $6,936.00 | 02/12/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST LLC | TRALOKINUMAB DRUG INTERACTION TRAIL | No dispute reported | 06/30/2026 | 686851939 |
| Principal investigator 1 | TOLMAR, INC. | $19,471.50 | 02/08/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | TOL3010B | No dispute reported | 06/30/2026 | 638019599 |
| Principal investigator 1 | Alkermes, Inc. | $1,937.25 | 02/06/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | No dispute reported | 06/30/2026 | 653526237 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $52,448.40 | 02/06/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 685006489 |
| Principal investigator 1 | Allergan Inc. | $8,025.60 | 02/05/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA | No dispute reported | 06/30/2026 | 670021305 |
| Principal investigator 1 | Allergan Inc. | $1,900.00 | 02/05/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670021673 |
| Principal investigator 1 | Allergan Inc. | $8,738.10 | 02/05/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC | No dispute reported | 06/30/2026 | 670021758 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 01/31/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526173 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 01/31/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | No dispute reported | 06/30/2026 | 653526195 |
| Principal investigator 1 | Alkermes, Inc. | $85.00 | 01/31/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | No dispute reported | 06/30/2026 | 653526197 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $27.56 | 01/31/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686564231 |
| Principal investigator 1 | Allergan Inc. | $47,850.00 | 01/29/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA | No dispute reported | 06/30/2026 | 670020523 |
| Principal investigator 1 | Allergan Inc. | $3,125.00 | 01/29/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC | No dispute reported | 06/30/2026 | 670020819 |
| Principal investigator 1 | Alkermes, Inc. | $105.00 | 01/25/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526171 |
| Principal investigator 1 | TOLMAR, INC. | $1,239.30 | 01/22/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | TOL3010B | No dispute reported | 06/30/2026 | 638019597 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $92,793.79 | 01/19/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A MULTICENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH BIPOLAR I DISORDER | No dispute reported | 06/30/2026 | 696053167 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 01/17/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | No dispute reported | 06/30/2026 | 653526213 |
| Principal investigator 1 | Allergan Inc. | $7,505.00 | 01/17/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670017711 |
| Principal investigator 1 | Alkermes, Inc. | $7,331.63 | 01/16/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | No dispute reported | 06/30/2026 | 653526233 |
| Principal investigator 1 | Alkermes, Inc. | $2,850.00 | 01/16/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | No dispute reported | 06/30/2026 | 653526235 |
| Principal investigator 1 | Allergan Inc. | $18,200.00 | 01/15/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC | No dispute reported | 06/30/2026 | 670016749 |
| Principal investigator 1 | Allergan Inc. | $400.00 | 01/15/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC | No dispute reported | 06/30/2026 | 670016863 |
| Principal investigator 1 | Allergan Inc. | $2,000.00 | 01/15/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA | No dispute reported | 06/30/2026 | 670017027 |
| Principal investigator 1 | Alkermes, Inc. | $12,825.00 | 01/10/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | No dispute reported | 06/30/2026 | 653526231 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $5.65 | 01/10/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686563805 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $338.00 | 01/10/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686563811 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $379,810.39 | 01/10/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | PROTOCOL 331-201-00080 A MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE ACUTE TREATMENT OF MANIC EPISODES, WITH OR WITHOUT MIXED FEATURES, ASSOCIATED WITH BIPOLAR I DISORDER | No dispute reported | 06/30/2026 | 696052951 |
| Principal investigator 1 | Allergan Inc. | $5,890.00 | 01/08/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 670015333 |
| Principal investigator 1 | Allergan Inc. | $48,315.10 | 01/08/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC | No dispute reported | 06/30/2026 | 670015413 |
| Principal investigator 1 | TOLMAR, INC. | $2,112.00 | 01/07/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | TOL3010B | No dispute reported | 06/30/2026 | 638019585 |
| Principal investigator 1 | TOLMAR, INC. | $332.00 | 01/07/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | TOL3010B | No dispute reported | 06/30/2026 | 638019589 |
| Principal investigator 1 | Alkermes, Inc. | $140.00 | 01/04/2019 | Non-covered Recipient Entity WOODLAND RESEARCH NORTHWEST, LLC. | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | No dispute reported | 06/30/2026 | 653526169 |
| Principal investigator 1 | Allergan Inc. | $8,400.00 | 01/03/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC | No dispute reported | 06/30/2026 | 670013821 |
| Principal investigator 1 | Allergan Inc. | $2,675.20 | 01/03/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA | No dispute reported | 06/30/2026 | 670014109 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $5.65 | 01/03/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686562619 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $64.00 | 01/03/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686562621 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $128.00 | 01/03/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 686562647 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $61,943.50 | 01/03/2019 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 685006483 |